2.67
Aclarion Inc stock is traded at $2.67, with a volume of 33,954.
It is down -0.74% in the last 24 hours and down -14.42% over the past month.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.
See More
Previous Close:
$2.69
Open:
$2.7
24h Volume:
33,954
Relative Volume:
0.36
Market Cap:
$6.57M
Revenue:
$77,900
Net Income/Loss:
$-8.05M
P/E Ratio:
-0.2893
EPS:
-9.2296
Net Cash Flow:
$-7.47M
1W Performance:
-10.70%
1M Performance:
-14.42%
6M Performance:
-36.12%
1Y Performance:
-63.57%
Aclarion Inc Stock (ACON) Company Profile
Name
Aclarion Inc
Sector
Industry
Phone
833 275 2266
Address
8181 ARISTA PLACE, BROOMFIELD
Compare ACON vs VEEV, BTSG, TEM, HQY, HNGE
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ACON
Aclarion Inc
|
2.67 | 6.62M | 77,900 | -8.05M | -7.47M | -9.2296 |
|
VEEV
Veeva Systems Inc
|
193.09 | 31.97B | 3.32B | 941.65M | 1.64B | 5.6161 |
|
BTSG
Brightspring Health Services Inc
|
69.67 | 13.67B | 13.65B | 169.86M | 412.12M | 1.0758 |
|
TEM
Tempus Ai Inc
|
58.67 | 10.04B | 1.36B | -302.91M | -219.93M | -1.7182 |
|
HQY
Healthequity Inc
|
94.50 | 8.00B | 1.34B | 230.70M | 440.96M | 2.6695 |
|
HNGE
Hinge Health Inc
|
89.31 | 6.96B | 646.34M | -512.40M | 202.76M | -6.6871 |
Aclarion Inc Stock (ACON) Latest News
Aclarion Inc. (ACON) Slides 2.6% as Support Levels Face Renewed PressureDouble Bottom - dars.gov.et
Price to sales forward of Aclarion, Inc. – NASDAQ:ACONW - TradingView
Number of shareholders of Aclarion, Inc. – NASDAQ:ACONW - TradingView
Price to earnings forward of Aclarion, Inc. – BOATS:ACONW - TradingView
ACON Q1 2026 Earnings: EPS Surprises to the Upside Despite Stock DeclinePerformance Review - DonanımHaber
Aclarion Inc. (ACON) Consolidates Near $3.02 as Micro-Cap Healthcare Stock Eyes Resistance at $3.17Bullish Sentiment - dars.gov.et
Aclarion Announces Texas Spine Care Center as New CLARITY Site - marketscreener.com
Aclarion adds Texas Spine Care Center to CLARITY trial - Investing.com
Aclarion adds Texas Spine Care Center to CLARITY trial By Investing.com - Investing.com Canada
Aclarion Inc. Warrant (ACONW) Slips 6.85%, Hovers at Critical $0.02 LevelLarge Cap Trends - DonanımHaber
Aclarion, Inc. Warrant 2022- on Aclarion Financial Disclosures & SEC Filings - TradingView
Aclarion Inc. Q1 2026 Earnings: EPS Surprise Drives Stock Rally Amid Revenue AbsenceTax Rate Impact - DonanımHaber
ACON Q1 2026 Earnings: EPS Surpasses Analyst Estimates Despite Lack of Revenue DisclosureFull Year Guidance - dars.gov.et
Enterprise value to EBIT forward of Aclarion, Inc. – NASDAQ:ACON - TradingView
Price to book forward of Aclarion, Inc. – NASDAQ:ACON - TradingView
A412BH Forecast — Price Target — Prediction for 2027 - TradingView
Aclarion, Inc. Actuals & Estimates (NASDAQ:ACON) - TradingView
ACON Forecast — Price Target — Prediction for 2027 - TradingView
Aclarion Inc (ACONW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aclarion Inc. (ACON) Q1 2026 Earnings: Narrower-than-expected Loss Drives EPS Beat, Yet Shares Slide 4.9%EPS Growth Report - DonanımHaber
Aclarion Inc. (ACON) Q1 2026 Earnings: EPS Surpasses Estimates with 15% Beat Despite No RevenueGAAP Earnings Report - dars.gov.et
Aclarion Inc (ACONW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ACON Q1 2026 Earnings: EPS Surprises Positively Despite Absence of RevenueAdjusted Earnings Analysis - Bölüm Sonu Canavarı
Aclarion Inc. Warrant (ACONW) Surges 38% From Penny Levels – But Caution WarrantedBPI Bull Correction - Město Břeclav
Aclarion Inc. Holds Steady Near Key Resistance Level (ACON)RTH Profile - dars.gov.et
Aclarion (ACON) upgraded to buy: Here's why - MSN
Aclarion Inc (ACONW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aclarion Inc (ACONW) Institutional Confidence - TradingKey
Aclarion Inc (ACONW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aclarion Inc (ACONW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aclarion Inc (ACONW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aclarion Inc (ACONW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aclarion Inc (ACONW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aclarion Inc (ACON) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aclarion Inc (ACON) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aclarion Inc (ACON) Institutional Confidence - TradingKey
Aclarion Inc (ACON) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aclarion Inc (ACON) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aclarion Inc (ACON) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aclarion Inc (ACON) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aclarion Inc (ACON) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aclarion Inc (ACON) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aclarion board rejects Echo Lake’s $4 per share takeover bid By Investing.com - Investing.com Nigeria
Aclarion Inc. (ACON) Q1 2026 Earnings: EPS Surpasses Estimates Despite Ongoing Revenue AbsenceEarnings Season Outlook - newsline.com
Aclarion Inc. (ACON) Slides Amid Light Trading, Support at $2.96 in FocusTRIN Signal - newsline.com
Aclarion (ACON) Chief Strategy Officer granted 55,000 RSUs vesting in 2027 - Stock Titan
Aclarion (ACON) director receives 20,000 RSUs vesting in 2027 - Stock Titan
Aclarion (NASDAQ: ACON) director receives 20,000 RSU equity grant - Stock Titan
Aclarion (ACON) CFO awarded 50,000 restricted stock units set to vest 2027 - Stock Titan
Aclarion (ACON) CEO Brent Ness receives 100,000 RSU equity award - Stock Titan
Aclarion (ACON) director awarded 20,000 RSUs vesting in 2027 - Stock Titan
Aclarion Inc Stock (ACON) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aclarion Inc Stock (ACON) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Neal David K | Director |
May 11 '26 |
Buy |
3.10 |
2,500 |
7,750 |
2,502 |
| Ness Brent | Chief Executive Officer |
May 11 '26 |
Buy |
3.18 |
6,289 |
19,999 |
6,300 |
| Wesemann William | Director |
May 06 '26 |
Buy |
3.30 |
1,562 |
5,155 |
1,563 |
| Ness Brent | Chief Executive Officer |
Nov 26 '25 |
Buy |
6.20 |
10 |
62 |
11 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):